ReviewBiomolecules & biomedicine2026
Stem cell-derived extracellular vesicles enriched with miR-22-3p for cataract treatment - Molecular mechanisms and therapeutic potential: A review.
Review in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cataracts, characterized by progressive lens opacification, affect a significant number of individuals globally, particularly the elderly and those with systemic diseases. Research on the pathogenesis of visual impairments has identified alterations in crystalline proteins, primarily driven by inflammation, apoptosis, oxidative stress, and fibrosis in lens epithelial cells, as the primary mechanisms contributing to cataract development. Current treatment options, including surgical lens implantation and stem cell therapy, have notable limitations, highlighting the need for alternative non-invasive therapies. Stem cell-derived extracellular vesicles (SC-EVs) have emerged as a novel therapeutic approach for various diseases. This review aims to comprehensively analyze the literature regarding the therapeutic potential of SC-EVs in cataract treatment, particularly when enriched with miR-22-3p. A literature search was conducted focusing on the molecular mechanisms of miR-22-3p in lens epithelial cells and cataract models, discussing its regulatory pathways in retinal and optic nerve injuries, as well as the advantages of utilizing SC-EVs as nanocarriers for targeted therapy. Studies indicate that miR-22-3p can inhibit crystalline remodeling by modulating gene expression and regulating apoptosis, fibrosis, oxidative stress, and inflammation. Consequently, it plays a role in the signaling pathways associated with cataracts and may also exhibit neuroprotective effects in neurons and retinal ganglion cells. By integrating current insights from research on cell-free EV therapies and the molecular mechanisms of miR-22-3p in cataract pathology, this review underscores the potential of miR-22-3p-enriched SC-EVs as a promising therapeutic option for cataracts. However, this hypothesis necessitates rigorous preclinical and clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.